Drug Research

Insilico Medicine has gone ahead with a multi-year research and development - R&D collaboration with Servier, of almost $888m, in order to develop and discover certain new oncology therapies. The partnership combines the AI drug discovery platforms of Insilico...

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Optimize late-stage pharmaceutical assets through strategic investment planning, risk management, and indication prioritization. Maximize R&D return on investment during the highest-stakes phase of drug development.

Accelerate pharmaceutical R&D decision-making by implementing modern governance frameworks that establish clear decision rights, defined escalation pathways and cross-functional ownership while maintaining strategic alignment and rigor.